Potential Epigenetic Modifications Implicated in Triple- To Quadruple-Negative Breast Cancer Transition: A Review

References

• Kang SP , MartelM , HarrisLN. Triple negative breast cancer: current understanding of biology and treatment options. Curr. Opin. Obstet. Gynecol.20(1), 40–46 (2008).
   PubMed Web of Science ®Google Scholar
• Prat A , PinedaE , AdamoBet al. Clinical implications of the intrinsic molecular subtypes of breast cancer. The Breast24(Suppl. 2), S26–S35 (2015).
   PubMedGoogle Scholar
• Khaled N , BidetY. New insights into the implication of epigenetic alterations in the EMT of triple negative breast cancer. Cancers11(4), 559 (2019).
   PubMed Web of Science ®Google Scholar
• Shimelis H , LaDucaH , HuCet al. Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing. JNCI J. Natl Cancer Inst.110(8), 855–862 (2018).
   Web of Science ®Google Scholar
• Philipovskiy A , DwivediAK , GamezRet al. Association between tumor mutation profile and clinical outcomes among Hispanic Latina women with triple-negative breast cancer. PloS One15(9), e0238262 (2020).
   PubMed Web of Science ®Google Scholar
• Uscanga-Perales GI , Santuario-FacioSK , Sanchez-DominguezCNet al. Genetic alterations of triple negative breast cancer (TNBC) in women from northeastern Mexico. Oncol. Lett.17(3), 3581–3588 (2019).
   PubMed Web of Science ®Google Scholar
• Angajala A , MothershedE , DavisMBet al. Quadruple negative breast cancers (QNBC) demonstrate subtype consistency among primary and recurrent or metastatic breast cancer. Transl. Oncol.12(3), 493–501 (2019).
   PubMed Web of Science ®Google Scholar
• Wright N , AkinyemijuT , SubhedarPet al. Targeting risk factors for reducing the racially disparate burden in breast cancer. Front Biosci.11, 136–160 (2019).
   Google Scholar
• Davis M , TripathiS , HughleyRet al. AR negative triple negative or ‘quadruple negative’ breast cancers in African American women have an enriched basal and immune signature. PloS One13(6), e0196909 (2018).
   PubMed Web of Science ®Google Scholar
• Huang M , WuJ , LingRet al. Quadruple negative breast cancer. Breast Cancer.27(4), 527–533 (2020).
   PubMed Web of Science ®Google Scholar
• Nandy D , RajamSM , DuttaD. A three layered histone epigenetics in breast cancer metastasis. Cell Biosci.10(1), 1–23 (2020).
   PubMed Web of Science ®Google Scholar
• Perreault AA , SprungerDM , VentersBJ. Epigenetic and transcriptional profiling of triple negative breast cancer. Sci. Data6(1), 1–9 (2019).
   PubMedGoogle Scholar
• Al-Khanbashi M , Al-MoundhriM. Micro-ribonucleic acid and carcinogenesis: breast cancer as an example. Oncol. Rev.9(1), 279 (2015).
   PubMedGoogle Scholar
• Shi Y , YangF , SunZet al. Differential microRNA expression is associated with androgen receptor expression in breast cancer. Mol. Med. Rep.15(1), 29–36 (2017).
   PubMed Web of Science ®Google Scholar
• Wu X , DingM , LinJ. Three-microRNA expression signature predicts survival in triple-negative breast cancer. Oncol. Lett.19(1), 301–308 (2020).
   PubMed Web of Science ®Google Scholar
• Bayraktar R , PichlerM , KanlikilicerPet al. “MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. Oncotarget8(7), 11641 (2017).
   PubMedGoogle Scholar
• Mo W , LiuQ , LinCCet al. mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancer. Clin. Cancer Res.22(7), 1699–1712 (2016).
   PubMed Web of Science ®Google Scholar
• Silver DP , RichardsonAL , EklundACet al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer AC. J. Clin. Oncol.28(7), 1145 (2010).
   PubMed Web of Science ®Google Scholar
• Kaleem M , PerwaizM , NurSMet al. Epigenetics of triple-negative breast cancer via natural compounds. Curr. Med. Chem.29(8), 1436–1458 (2022).
   PubMed Web of Science ®Google Scholar
• Selmin OI , DonovanMG , StillwaterBJet al. Epigenetic regulation and dietary control of triple negative breast cancer. Front. Nutr.7, 159 (2020).
   PubMed Web of Science ®Google Scholar
• Emens LA , CruzC , EderJPet al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol.5(1), 74–82 (2019).
   PubMed Web of Science ®Google Scholar
• Jiao X , WangM , ZhangZet al. Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. Breast Cancer Res.23(1), 1–15 (2021).
   PubMed Web of Science ®Google Scholar
• Saini G , BhattaraiS , GogineniKet al. Quadruple-negative breast cancer: an uneven playing field. JCO Glob. Oncol.6, 233–237 (2020).
   PubMedGoogle Scholar
• Bhattarai S , SainiG , GogineniKet al. Quadruple-negative breast cancer: novel implications for a new disease. Breast Cancer Res.22(1), 1–11 (2020).
   Web of Science ®Google Scholar
• Jansson S , BendahlPO , GrabauDAet al. The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer. PLoS One9(7), e102176 (2014).
   PubMed Web of Science ®Google Scholar
• Johansson I , AaltonenKE , EbbessonAet al. Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis. Genes Chromosomes Cancer51(4), 375–383 (2012).
   PubMed Web of Science ®Google Scholar
• Feng Y , SpeziaM , HuangSet al. “Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis.5(2), 77–106 (2018).
   PubMed Web of Science ®Google Scholar
• Hafez MM , Al-ShabanahOA , Al-RejaieSSet al. Increased hypermethylation of glutathione S-transferase P1, DNA-binding protein inhibitor, death associated protein kinase and paired box protein-5 genes in triple-negative breast cancer Saudi females. Asian Pac. J. Cancer Prev.16(2), 541–549 (2015).
   PubMedGoogle Scholar
• Chen YC , SahooS , BrienRet al. Single-cell RNA-sequencing of migratory breast cancer cells: discovering genes associated with cancer metastasis. Analyst144(24), 7296–7309 (2019).
   PubMed Web of Science ®Google Scholar
• Moosavi A , ArdekaniAM. Role of epigenetics in biology and human diseases AM. Iran. Biomed. J.20(5), 246 (2016).
   PubMedGoogle Scholar
• Yin L , DuanJJ , BianXW , YuS. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res.22(1), 1–13 (2020).
   Web of Science ®Google Scholar
• Kagara N , HuynhKT , KuoCet al. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer. Am. J. Pathol.181(1), 257–267 (2012).
   PubMed Web of Science ®Google Scholar
• Sharma S , KellyTK , JonesPA. Epigenetics in cancer. Carcinogenesis31(1), 27–36 (2010).
   PubMed Web of Science ®Google Scholar
• Ciriello G , SinhaR , HoadleyKAet al. The molecular diversity of luminal A breast tumors. Breast Cancer Res. Treat.141(3), 409–420 (2013).
   PubMed Web of Science ®Google Scholar
• Bareche Y , VenetD , IgnatiadisMet al. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Ann. Oncol.29(4), 895–902 (2018).
   PubMed Web of Science ®Google Scholar
• Dattilo MA , BenzoY , HerreraLMet al. Regulatory mechanisms leading to differential acyl-CoA synthetase 4 expression in breast cancer cells. Sci. Rep.9(1), 1–13 (2019).
   PubMedGoogle Scholar
• Bao L , QianZ , LyngMBet al. Coexisting genomic aberrations associated with lymph node metastasis in breast cancer. J. Clin. Invest.128(6), 2310–2324 (2018).
   PubMed Web of Science ®Google Scholar
• Bhattarai S , SugitaBM , BortolettoSMet al. QNBC is associated with high genomic instability characterized by copy number alterations and miRNA deregulation. Int. J. Mol. Sci.22(21), 11548 (2021).
   PubMed Web of Science ®Google Scholar
• Sporikova Z , KoudelakovaV , TrojanecRet al. Genetic markers in triple-negative breast cancer. Clin. Breast Cancer18(5), e841–e850 (2018).
   PubMed Web of Science ®Google Scholar
• Shah SP , RothA , GoyaRet al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature486(7403), 395–399 (2012).
   PubMed Web of Science ®Google Scholar
• Koboldt D , FultonR , McLellanMet al. Comprehensive molecular portraits of human breast tumours. Nature490(7418), 61–70 (2012).
   PubMed Web of Science ®Google Scholar
• Couch FJ , HartSN , SharmaPet al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J. Clin. Oncol.33(4), 304 (2015).
   PubMed Web of Science ®Google Scholar
• Jones N , BonnetF , SfarSet al. Comprehensive analysis of PTEN status in breast carcinomas. Int. J. Cancer133(2), 323–334 (2013).
   PubMed Web of Science ®Google Scholar
• Fedele CG , OomsLM , HoMet al. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc. Natl Acad. Sci.107(51), 22231–22236 (2010).
   PubMed Web of Science ®Google Scholar
• McGhan LJ , McCulloughAE , ProtheroeCAet al. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype. Ann. Surg. Oncol.21(2), 361–367 (2014).
   PubMed Web of Science ®Google Scholar
• Naderi A , Hughes-DaviesL. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia10(6), 542–548 (2008).
   PubMed Web of Science ®Google Scholar
• Sher G , SalmanNA , KhanAQ et al. Epigenetic andbreast cancer therapy: Promising diagnostic and therapeutic applications. Semin. Cancer Biol. (2020).
   Web of Science ®Google Scholar
• Kagara N , HuynhKT , KuoCet al. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer. Am. J. Pathol.181(1), 257–267 (2012).
   PubMed Web of Science ®Google Scholar
• Garrido-Castro AC , LinNU , PolyakK. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov.9(2), 176–198 (2019).
   PubMed Web of Science ®Google Scholar
• Kazim Z , WahabiK , PerwezAet al. PTEN genetic and epigenetic alterations define distinct subgroups in North Indian breast cancer patients. Asian Pac. J. Cancer Prev. APJCP20(1), 269 (2019).
   PubMedGoogle Scholar
• Li G , WangD , MaWet al. Transcriptomic and epigenetic analysis of breast cancer stem cells. Epigenomics10(6), 765–783 (2018).
   PubMed Web of Science ®Google Scholar
• Zolota V , TzelepiV , PiperigkouZet al. Epigenetic alterations in triple-negative breast cancer – the critical role of extracellular matrix. Cancers13(4), 713 (2021).
   PubMed Web of Science ®Google Scholar
• Naldi I , TarantaM , GherardiniLet al. Novel epigenetic target therapy for prostate cancer: a preclinical study. PLoS One9(5), e98101 (2014).
   PubMed Web of Science ®Google Scholar
• Heard E , MartienssenRA. Transgenerational epigenetic inheritance: myths and mechanisms. Cell157(1), 95–109 (2014).
   PubMed Web of Science ®Google Scholar
• Dai X , MaR , ZhaoXet al. Epigenetic profiles capturing breast cancer stemness for triple negative breast cancer control. Epigenomics11(16), 1811–1825 (2019).
   PubMed Web of Science ®Google Scholar
• He J , PengR , YuanZet al. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med. Oncol.29(2), 406–410 (2012).
   PubMed Web of Science ®Google Scholar
• Keyvani-Ghamsari S , KhorsandiK , RasulAet al. Current understanding of epigenetics mechanism as a novel target in reducing cancer stem cells resistance. Clin. Epigenetics13(1), 1–31 (2021).
   PubMed Web of Science ®Google Scholar
• Grønbaek K , HotherC , JonesPA. Epigenetic changes in cancer. APMIS Acta Pathol. Microbiol. Immunol. Scand.115(10), 1039–1059 (2007).
   PubMed Web of Science ®Google Scholar
• Temian DC , PopLA , IrimieAIet al. The epigenetics of triple-negative and basal-like breast cancer: current knowledge. J. Breast Cancer21(3), 233–243 (2018).
   PubMed Web of Science ®Google Scholar
• Llinàs-Arias P , Íñiguez-MuñozS , McCannKet al. Epigenetic regulation of immunotherapy response in triple-negative breast cancer. Cancers13(16), 4139 (2021).
   PubMed Web of Science ®Google Scholar
• Moghazy TF , ElattarHA , EldeebMKet al. Methylation of glutathione-S-transferase P1 promotor in Egyptian females with breast cancer. Asian Pac. J. Cancer Prev. APJCP20(8), 2523 (2019).
   PubMedGoogle Scholar
• Morizono A , TanabeM , IkemuraMet al. Loss of BRCA1 expression and morphological features associated with BRCA1 promoter methylation status in triple-negative breast cancer. J. Hum. Genet.66(8), 785–793 (2021).
   PubMed Web of Science ®Google Scholar
• Prajzendanc K , DomagałaP , HybiakJet al. BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer. Int. J. Cancer146(5), 1293–1298 (2020).
   PubMed Web of Science ®Google Scholar
• Ruscito I , GasparriML , DeMarco MPet al. The clinical and pathological profile of BRCA1 gene methylated breast cancer women: a meta-analysis. Cancers13(6), 1391 (2021).
   PubMed Web of Science ®Google Scholar
• Al-Yousef N , ShinwariZ , Al-ShahraniBet al. Curcumin induces re-expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines. Oncol. Rep.43(3), 827–838 (2020).
   PubMed Web of Science ®Google Scholar
• Hon JDC , SinghB , SahinAet al. Breast cancer molecular subtypes: from TNBC to QNBC. Am. J. Cancer Res.6(9), 1864 (2016).
   PubMed Web of Science ®Google Scholar
• Velasco-Velázquez MA , HomsiN , DeLa Fuente M , PestellRG. Breast cancer stem cells. Int. J. Biochem. Cell Biol.44(4), 573–577 (2012).
   PubMed Web of Science ®Google Scholar
• Ralser DJ , KlümperN , GevenslebenHet al. Molecular and immune correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA methylation in triple negative breast cancer. J. Immunother.44(8), 319–324 (2021).
   PubMed Web of Science ®Google Scholar
• Wang F , CaoX , YinLet al. Identification of SCARA5 gene as a potential immune-related biomarker for triple-negative breast cancer by integrated analysis. DNA Cell Biol.39(10), 1813–1824 (2020).
   PubMed Web of Science ®Google Scholar
• Mittendorf EA , PhilipsAV , Meric-BernstamFet al. PD-L1 expression in triple-negative breast cance”. Cancer Immunol. Res.2(4), 361–370 (2014).
   PubMed Web of Science ®Google Scholar
• Kozomara Z , SupicG , KrivokucaAet al. Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia. J. BUON23, 684–691 (2018).
   PubMed Web of Science ®Google Scholar
• Manica GC , RibeiroCF , DeOliveira MAet al. Down regulation of ADAM33 as a predictive biomarker of aggressive breast cancer. Sci. Rep.7(1), 1–13 (2017).
   PubMedGoogle Scholar
• Miyagawa Y , MatsushitaY , SuzukiHet al. Frequent downregulation of LRRC26 by epigenetic alterations is involved in the malignant progression of triple-negative breast cancer. Int. J. Oncol.52(5), 1539–1558 (2018).
   PubMed Web of Science ®Google Scholar
• Wang H , WuD , CaiLet al. Aberrant methylation of WD-repeat protein 41 contributes to tumour progression in triple-negative breast cancer. J. Cell. Mol. Med.24(12), 6869–6882 (2020).
   PubMed Web of Science ®Google Scholar
• Xia J , LüZD , ZhouPHet al. DNA methylation modification of BRMS1 in triple-negative breast cancer and its correlation with tumor metastasis. Zhonghua Yi Xue Za Zhi97(44), 3483–3487 (2017).
   PubMedGoogle Scholar
• Paço A , Leitão-CastroJ , FreitasR. Epigenetic regulation of CDH1 is altered after HOXB7-silencing in MDA-MB-468 triple-negative breast cancer cells. Genes12(10), 1575 (2021).
   PubMed Web of Science ®Google Scholar
• Rozova VS , AnwerAG , GullerAEet al. Machine learning reveals mesenchymal breast carcinoma cell adaptation in response to matrix stiffness. PLoS Comput. Biol.17(7), e1009193 (2021).
   PubMed Web of Science ®Google Scholar
• Noyan S , OzketenAA , GurdalHet al. miR-770-5p regulates EMT and invasion in TNBC cells by targeting DNMT3A. Cell. Signal.83, 109996 (2021).
   PubMed Web of Science ®Google Scholar
• Roll JD , RivenbarkAG , JonesWDet al. DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines. Mol. Cancer7(1), 1–14 (2008).
   PubMedGoogle Scholar
• Cha Y , JungW , KooJ. Expression of DNA methylation-related proteins in metastatic breast cancer. Neoplasma64(3), 412–420 (2017).
   PubMed Web of Science ®Google Scholar
• Yu J , QinB , MoyerAMet al. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J. Clin. Invest.128(6), 2376–2388 (2018).
   PubMed Web of Science ®Google Scholar
• Kim YJ , SungM , OhEet al. Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer. Cancer Biol. Ther.19(4), 335–345 (2018).
   PubMed Web of Science ®Google Scholar
• Schech A , KaziA , YuSet al. Histone deacetylase inhibitor entinostat inhibits tumor-initiating cells in triple-negative breast cancer cells. Mol. Cancer Ther.14(8), 1848–1857 (2015).
   PubMed Web of Science ®Google Scholar
• Yusuf AP , AbubakarMB , MalamiIet al. Zinc metalloproteins in epigenetics and their crosstalk. Life11(3), 186 (2021).
   PubMedGoogle Scholar
• Zheng Q , FanH , MengZet al. Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription. Acta Biochim. Biophys. Sin.50(9), 897–904 (2018).
   Google Scholar
• Gao B , LiuX , LiZet al. Overexpression of EZH2/NSD2 histone methyltransferase axis predicts poor prognosis and accelerates tumor progression in triple-negative breast cancer. Front. Oncol.10, 3421 (2021).
   Web of Science ®Google Scholar
• Kundur S , PrayagA , SelvakumarPet al. Synergistic anticancer action of quercetin and curcumin against triple-negative breast cancer cell lines. J. Cell. Physiol.234(7), 11103–11118 (2019)
   PubMed Web of Science ®Google Scholar
• Bao C , LiuT , QianLet al. Shikonin inhibits migration and invasion of triple-negative breast cancer cells by suppressing epithelial–mesenchymal transition via miR-17-5p/PTEN/Akt pathway. J. Cancer12(1), 76 (2021).
   PubMed Web of Science ®Google Scholar
• Maiti A , QiQ , PengXet al. Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells. Int. J. Oncol.55(1), 116–130 (2019).
   PubMed Web of Science ®Google Scholar
• Loh HY , NormanBP , LaiKSet al. The regulatory role of microRNAs in breast cancer. Int. J. Mol. Sci.20(19), 4940 (2019).
   PubMed Web of Science ®Google Scholar
• Peng Y , CroceCM. The role of microRNAs in human cancer. Signal Transduct. Target. Ther.1, 15004 (2016).
   PubMed Web of Science ®Google Scholar
• Paul U , BanerjeeS. The functional significance and cross-talk of non-coding RNAs in triple negative and quadruple negative breast cancer. Mol. Biol. Rep.1–20 (2022).
   Web of Science ®Google Scholar
• Qattan A , Al-TweigeriT , SulemanK. Translational implications of dysregulated pathways and microRNA regulation in quadruple-negative breast cancer. Biomedicines10(2), 366 (2022).
   PubMed Web of Science ®Google Scholar
• Yao M , WangS , ChenLet al. Research on correlations of miR-585 expression with progression and prognosis of triple-negative breast cancer. Clin. Exp. Med.1–7 (2021).
   PubMed Web of Science ®Google Scholar
• Turashvili G , LightbodyED , TyryshkinKet al. Novel prognostic and predictive microRNA targets for triple-negative breast cancer. FASEB J.32(11), 5937–5954 (2018).
   Web of Science ®Google Scholar
• Wu J , ZhouZ. MicroRNA-432 acts as a prognostic biomarker and an inhibitor of cell proliferation, migration, and invasion in breast cancer. Clin. Breast Cancer.21(4), e462–e470 (2021).
   PubMed Web of Science ®Google Scholar
• Wang W , ZhangW , WuJet al. miR-522 regulates cell proliferation, migration, invasion capacities and acts as a potential biomarker to predict prognosis in triple-negative breast cancer. Clin. Exp. Med.1–8 (2021).
   Web of Science ®Google Scholar
• Gao S , ShiP , TianZet al. Overexpression of miR-1225 promotes the progression of breast cancer, resulting in poor prognosis. Clin. Exp. Med.21(2), 287–296 (2021).
   PubMed Web of Science ®Google Scholar
• Li HY , LiangJL , KuoYLet al. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer. Breast Cancer Res.19(1), 1–14 (2017).
   PubMedGoogle Scholar
• Kleivi Sahlberg K , BottaiG , NaumeBet al. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.21(5), 1207–1214 (2015).
   PubMed Web of Science ®Google Scholar
• Lü L , MaoX , ShiPet al. MicroRNAs in the prognosis of triple-negative breast cancer: a systematic review and meta-analysis. Medicine (Baltimore)96(22), e7085 (2017).
   PubMed Web of Science ®Google Scholar
• Thakur S , GroverRK , GuptaSet al. Identification of specific miRNA signature in paired sera and tissue samples of Indian women with triple negative breast cancer. PloS One11(7), e0158946 (2016).
   PubMed Web of Science ®Google Scholar
• An P , LiJ , LuLet al. Histone deacetylase 8 triggers the migration of triple negative breast cancer cells via regulation of YAP signals. Eur. J. Pharmacol.845, 16–23 (2019).
   PubMed Web of Science ®Google Scholar
• Jarrard DF , KinoshitaH , ShiYet al. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res.58(23), 5310–5314 (1998).
   PubMed Web of Science ®Google Scholar
• Nakayama T , WatanabeM , SuzukiHet al. Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab. Invest.80(12), 1789–1796 (2000).
   PubMed Web of Science ®Google Scholar
• Takahashi S , InagumaS , SakakibaraMet al. DNA methylation in the androgen receptor gene promoter region in rat prostate cancers. The Prostate52(1), 82–88 (2002).
   PubMed Web of Science ®Google Scholar
• Chu M , ChangY , LiPet al. Androgen receptor is negatively correlated with the methylation-mediated transcriptional repression of miR-375 in human prostate cancer cells. Oncol. Rep.31(1), 34–40 (2014).
   PubMed Web of Science ®Google Scholar
• Bandini E , FaniniF. MicroRNAs and androgen receptor: emerging players in breast cancer. Front. Genet.10, 203 (2019).
   PubMed Web of Science ®Google Scholar
• Nakano K , MikiY , HataSet al. Identification of androgen-responsive microRNAs and androgen-related genes in breast cancer. Anticancer Res.33(11), 4811–4819 (2013).
   PubMed Web of Science ®Google Scholar
• Yang F , ShenY , ZhangWet al. An androgen receptor negatively induced long non-coding RNA ARNILA binding to miR-204 promotes the invasion and metastasis of triple-negative breast cancer. Cell Death Differ.25(12), 2209–2220 (2018).
   PubMed Web of Science ®Google Scholar
• Kuwata H , NakataniE , Shimbara-MatsubayashiSet al. Long-chain acyl-CoA synthetase 4 participates in the formation of highly unsaturated fatty acid-containing phospholipids in murine macrophages. Biochim. Biophys. Acta BBA – Mol. Cell Biol. Lipids1864(11), 1606–1618 (2019).
   PubMed Web of Science ®Google Scholar
• Wu X , LiY , WangJet al. Long chain fatty acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancer. PloS One8(10), e77060 (2013).
   PubMed Web of Science ®Google Scholar
• Monaco ME , CreightonCJ , LeePet al. Expression of long-chain fatty acyl-CoA synthetase 4 in breast and prostate cancers is associated with sex steroid hormone receptor negativity. Transl. Oncol.3(2), 91–98 (2010).
   PubMed Web of Science ®Google Scholar
• Talley JT , MohiuddinSS. Biochemistry, fatty acid oxidation. In: StatPearls [Internet]StatPearls Publishing, FL, USA (2021).
   Google Scholar
• Garmpis N , DamaskosC , GarmpiAet al. Histone deacetylases as new therapeutic targets in triple-negative breast cancer: progress and promises. Cancer Genomics Proteomics14(5), 299–313 (2017).
   PubMed Web of Science ®Google Scholar
• Damaskos C , ValsamiS , SpartalisEet al. Histone deacetylase inhibitors: a novel therapeutic weapon against medullary thyroid cancer? Anticancer Res. 36(10), 5019–5024 (2016).
   PubMed Web of Science ®Google Scholar
• Wu S , LuoZ , YuPJet al. Suberoylanilide hydroxamic acid (SAHA) promotes the epithelial mesenchymal transition of triple negative breast cancer cells via HDAC8/FOXA1 signals. Biol. Chem.397(1), 75–83 (2016).
   PubMed Web of Science ®Google Scholar
• Kashiwagi S , YashiroM , TakashimaTet al. Significance of E-cadherin expression in triple-negative breast cancer. Br. J. Cancer103(2), 249–255 (2010).
   PubMed Web of Science ®Google Scholar
• Tang D , XuS , ZhangQet al. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Med. Oncol.29(2), 526–533 (2012).
   PubMed Web of Science ®Google Scholar
• Tate CR , RhodesLV , SegarHCet al. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res.14(3), 1–15 (2012).
   Web of Science ®Google Scholar
• Merino VF , NguyenN , JinKet al. Combined treatment with epigenetic, differentiating, and chemotherapeutic agents cooperatively targets tumor-initiating cells in triple-negative breast cancer. Cancer Res.76(7), 2013–2024 (2016).
   PubMed Web of Science ®Google Scholar
• Peluffo G , SubedeeA , HarperNWet al. EN1 is a transcriptional dependency in triple-negative breast cancer associated with brain metastasis. Cancer Res.79(16), 4173–4183 (2019).
   PubMed Web of Science ®Google Scholar
• Davie JR . Inhibition of histone deacetylase activity by butyrate. J. Nutr.133(Suppl. 7), S2485–S2493 (2003).
   Web of Science ®Google Scholar
• ElMoneim HMA , ZaghloulNM. Expression of E-cadherin, N-cadherin and snail and their correlation with clinicopathological variants: an immunohistochemical study of 132 invasive ductal breast carcinomas in Egypt. Clin. Sao Paulo Braz.66(10), 1765–1771 (2011).
   PubMed Web of Science ®Google Scholar